Akcea and Ionis Announce Publication of Long-Term Clinical Data of TEGSEDI® in Patients with Polyneuropathy Driven by hATTR Amyloidosis
Posted December 28, 2020 by akceacanada
Results from the ongoing, (OLE) study of the pivotal NEURO-TTR trial published in the European Journal of Neurology show that patients treated with TEGSEDI® (inotersen) experience.
Feature News
Patients administered TEGSEDI also experienced clinically relevant improvements in measures of quality of life compared to the natural history of the disease
No new safety signals were identified in the OLE study
-- END ---
| Contact Email | [email protected] |
| Issued By | Akcea Therapeutics Inc. Canada |
| Phone | (617) 207-0202 |
| Business Address | 1220-55 Metcalfe St., Ottawa, ON K1P 6L5 |
| Country | Canada |
| Categories | Medical |
| Tags | hattr treatment canada , hattr tretament testing , tegsedi , tegsedi testing |
| Last Updated | December 28, 2020 |